Skip to main content
Premium Trial:

Request an Annual Quote

Bluebee Closes €10M Series A Financing

NEW YORK (GenomeWeb) – Bluebee has closed a Series A financing round in which it raised €10 million ($11.6 million) from new investors including Capricorn ICT Arkiv, Korys, and Biover II, and from existing shareholders including Buysse & Partners and the Bluebee management team.

The Dutch informatics firm plans to use the funds to further develop its cloud-based genomic analysis platform, which combines distributed computing capabilities with accelerated hardware to help customers process large volumes of genomic data quickly and efficiently.

"This is an exciting time for Bluebee," CEO Hans Cobben said in a statement. "After a successful market introduction in the second half of 2014, and with a rapidly growing customer base, the time is right to shift gears. This funding will significantly boost our capacity to support our growth. We appreciate the continued support of our existing shareholders, and look forward to working with our new investors."

Bluebee has also tapped Annie Vereecken to serve as chairman of its board of advisors, the company said. Vereecken is the founder and former owner of the AML-Labo Riatol labs, which was sold to Sonic Healthcare in 2010.

Last year, Bluebee raised €1.8 million in financing from Buysse & Partners and Delft University of Technology.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.